Paracentesis Underutilized in Patients With Cirrhosis, Ascites

This article originally appeared here.
Share this content:
Paracentesis Underutilized in Patients With Cirrhosis, Ascites
Paracentesis Underutilized in Patients With Cirrhosis, Ascites

FRIDAY, Dec. 11, 2015 (HealthDay News) -- For patients admitted with diagnoses of cirrhosis and ascites, paracentesis is associated with decreased in-hospital mortality but is underutilized, according to a study published online Dec. 8 in the Journal of Gastroenterology and Hepatology.

John N. Gaetano, M.D., from the University of Chicago, and colleagues identified 31,614 adults, non-electively admitted with diagnoses of cirrhosis and ascites. Utilization and outcomes of paracentesis were examined.

The researchers found that 51 percent of the hospitalized patients underwent paracentesis. The overall in-hospital mortality rate was 7.6 percent, with increased mortality seen among patients who did not versus those who did undergo paracentesis (8.9 versus 6.3 percent; P < 0.001). In-hospital mortality was 1.83-fold higher for patients who did not receive paracentesis versus those who did receive paracentesis. There was a reduction in mortality for early paracentesis versus late paracentesis (5.5 versus 7.5 percent). Less frequent use of early paracentesis was seen for patients admitted on a weekend (50 versus 62 percent for those admitted on a weekday; adjusted odds ratio, 1.12). Early paracentesis correlated with shorter length of stay and decreased hospitalization costs among patients diagnosed with spontaneous bacterial peritonitis (both P < 0.001).

"[These data support] the use of paracentesis as a key inpatient quality measure among hospitalized adults with cirrhosis," the authors write. "Future studies are needed to investigate the barriers to paracentesis use on admission."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »